Physician profile
Emilynne Buchanan
NPI 1194145425
$6,108.38
in general payments reported to CMS, 2019-2025
27 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,454 · 2020: $131 · 2021: $584 · 2022: $940 · 2023: $343 · 2024: $398 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,000.00 | 2019 | |
| Abbvie INC. | $721.58 | 2019-2024 | |
| Astellas Pharma US INC | $502.86 | 2019-2025 | Veozah, Myrbetriq |
| Baxter Healthcare | $208.45 | 2021-2022 | |
| Myovant Sciences INC. | $175.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.55 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $142.68 | 2021-2023 | |
| Exeltis, USA INC. | $111.70 | 2021-2024 | Slynd |
| Aspira Women'S Health INC | $110.21 | 2021-2022 | |
| Organon LLC | $106.69 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $97.57 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Sumitomo Pharma America, INC. | $96.98 | 2023-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $93.12 | 2021-2022 | |
| Daiichi Sankyo INC. | $71.23 | 2020-2022 | |
| Ethicon US, LLC | $70.68 | 2024 | Enseal X1, Enseal |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.31 | 2019-2025 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $65.56 | 2021-2022 | |
| Pfizer INC. | $58.90 | 2021-2025 | |
| Hologic Sales and Service, LLC | $50.54 | 2021-2022 | |
| Evofem Biosciences, INC. | $41.40 | 2022-2023 | Phexxi |
| Agile Therapeutics, INC. | $38.80 | 2021-2022 | |
| Millicent US INC | $31.78 | 2023-2024 | Femring, Intrarosa |
| Depuy Synthes Sales INC. | $23.52 | 2021 | |
| Scynexis, INC. | $22.24 | 2022 | |
| Glaxosmithkline, LLC. | $19.21 | 2024 | Shingrix |
| Seqirus USA INC | $15.47 | 2025 | Flucelvax, Fluad |
| Covidien LP | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilynne Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.